- Home
- RPRX
RPRX
Royalty Pharma plc
as of 12-15-2025 3:36pm EST
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 16.2B | IPO Year: | 2020 |
| Target Price: | $45.75 | AVG Volume (30 days): | 4.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.75 | EPS Growth: | -31.41 |
| 52 Week Low/High: | $24.05 - $41.24 | Next Earning Date: | 11-05-2025 |
| Revenue: | $2,349,844,000 | Revenue Growth: | 3.70% |
| Revenue Growth (this year): | 37.13% | Revenue Growth (next year): | 1.48% |
AI-Powered RPRX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Royalty Pharma plc (RPRX)
EVP, Research & Investments
Avg Cost/Share
$39.15
Shares
41,576
Total Value
$1,627,814.99
Owned After
160,000
EVP & CFO
Avg Cost/Share
$39.87
Shares
69,582
Total Value
$2,773,956.01
Owned After
592,492
EVP, Research & Investments
Avg Cost/Share
$39.91
Shares
41,575
Total Value
$1,659,488.82
Owned After
160,000
EVP & CFO
Avg Cost/Share
$38.31
Shares
69,582
Total Value
$2,682,505.45
Owned After
592,492
EVP & CFO
Avg Cost/Share
$39.30
Shares
69,594
Total Value
$2,735,329.16
Owned After
592,492
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Urist Marshall | RPRX | EVP, Research & Investments | Dec 5, 2025 | Sell | $39.15 | 41,576 | $1,627,814.99 | 160,000 | |
| Coyne Terrance P. | RPRX | EVP & CFO | Dec 1, 2025 | Sell | $39.87 | 69,582 | $2,773,956.01 | 592,492 | |
| Urist Marshall | RPRX | EVP, Research & Investments | Dec 1, 2025 | Sell | $39.91 | 41,575 | $1,659,488.82 | 160,000 | |
| Coyne Terrance P. | RPRX | EVP & CFO | Nov 24, 2025 | Sell | $38.31 | 69,582 | $2,682,505.45 | 592,492 | |
| Coyne Terrance P. | RPRX | EVP & CFO | Nov 17, 2025 | Sell | $39.30 | 69,594 | $2,735,329.16 | 592,492 |
Compare RPRX vs Leading Stocks
See how RPRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RPRX Royalty Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.